An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Amylyx Announces Pivotal Phase 3 GLP-1 Trial Design in Post-Bariatric Hypoglycemia On December 4, Amylyx announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric...
The Endocrine Society’s 2025 recipient of the Gerald D. Aurbach Award for Outstanding Translational Research, V. Krishna Chatterjee, MD, tells Endocrine News why it’s so important for clinicians and basic scientists to work together to improve human health. In 2021, when our lives were still gripped by the deadly COVID-19 pandemic, V. Krishna Chatterjee, MD,...2024 Marked Year of Significant Accomplishments at the Society
It has been a remarkable year for the Endocrine Society! As the year draws to a close it’s timely to reflect on what we achieved over the past 12 months. Over this year we launched two new meetings, merged with an endocrine program directors’ association, entered partnerships to enhance our educational offerings, and created a... An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Exelixis, Inc. on November 26 announced that the U.S. Food and Drug Administration (FDA) has notified the company...
If it’s November, then it must be time for an issue of Endocrine News devoted entirely to the science and treatment of people living with diabetes to coincide with Diabetes Awareness Month in the United States. Each year we highlight the work of our members around the world and the research they conduct that contributes... Recent studies shed light on the safety and efficacy of diabetes medications GLP-1 receptor agonists, SGLT2 inhibitors, and DPP4 inhibitors were all scrutinized in new research presented at ENDO 2024. While most of the results were good news for the impact of medications for people with type 2 diabetes, clinicians prescribing these medications should be...
New research explores the impact of prediabetes on a Mexican population. According to a study presented at ENDO 2024, prediabetes increases the risk of dying before the age of 75, particularly due to heart disease, kidney disease, and acute diabetic complications in Mexican populations. The study’s author, Carlos A. Fermín-Martínez, MD, discusses his findings and...
HDL Quality, Not Quantity, Contributes to the First Sign of Alzheimer’s Disease in Women
Higher levels of HDL-C—known as the “good cholesterol”—have been shown to correlate with heightened risk for Alzheimer’s disease, according to a study recently published in The Journal of Clinical Endocrinology & Metabolism. Once women reach the menopause transition, it’s a matter of the quality, rather than quantity, of the total cholesterol carried by HDL particles circulating in a...
